Concepedia

Author

Margherita Rimini

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

Francesca Salani, Jean-François Dufour, M Rimini, M. Rimini, M.L. Maria Luisa De Rimini, Margherita Rimini, Massimiliano Rimini, Rimini, Margherita

159

Publications

2.1K

Citations

25

H-Index

38

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoVita-Salute San Raffaele UniversityIstituto Oncologico VenetoIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleAzienda Ospedaliera Universitaria Pisana
MR

About

Margherita Rimini is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, pathology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

16

454

2

Hepatology

8

8

304

3

Health Sciences

4

4

105

4

Cell Biology

1

1

10

5

Gastroenterology

1

1

21

Margherita Rimini

×

46

Publications

1.3K

Citations

21

H-Index

YearCitations

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima,

ESMO Open

2022

124

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada,

European Journal of Cancer

2022

123

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Margherita Rimini, Lorenzo Fornaro, Sara Lonardi,

Liver International

2023

110

Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Andrea Casadei‐Gardini, Mario Scartozzi, Toshifumi Tada,

Liver International

2021

60

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada,

European Journal of Cancer

2023

50

Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study

Margherita Rimini, Shigeo Shimose, Sara Lonardi,

Hepatology Research

2021

44

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

Margherita Rimini, Masatoshi Kudo, Toshifumi Tada,

ESMO Open

2021

43

Effect of the combination of clarithromycin and amikacin on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection

Oscar Cirioni, Roberto Ghiselli, Carmela Silvestri,

Journal of Antimicrobial Chemotherapy

2011

39

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Andrea Casadei‐Gardini, Margherita Rimini, Masatoshi Kudo,

Liver Cancer

2022

37

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Valentina Burgio, Massimo Iavarone, G.G. Di Costanzo,

Cancer Management and Research

2021

35

Page 1